Pricing Log in Create free account
Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%
Market cap
$82.0B
P/E
18.9×
Fwd P/E
16.5×
Dividend yield
0.47%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a EV/Sales of 4.9×. Over the past ten years it has ranged from 3.4× (June 2025) to 17.9× (June 2015); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 5.3× 4.91%
FY2024 5.1× (25.99%)
FY2023 6.9× 13.35%
FY2022 6.0× 50.61%
FY2021 4.0× (35.12%)
FY2020 6.2× 5.41%
FY2019 5.9× (20.91%)
FY2018 7.4× 9.08%
FY2017 6.8× (15.33%)
FY2016 8.0× (40.32%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 3.8× (23.78%)
Mar 2026 5.0× (5.44%)
Dec 2025 5.3× 40.40%
Sep 2025 3.8× 3.80%
42 more quarters

Against its own ten years

Low 3.4× High 17.9×
Ten-year median 6.4×
Current reading's percentile 20

EV/Sales against peers

Company EV/Sales
REGN Regeneron Pharmaceuticals, Inc. 4.9×
ALNY Alnylam Pharmaceuticals, Inc. compare 6.0×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.1×
ARGX argenex SE compare 8.9×
VRTX Vertex Pharmaceuticals Incorporated compare 9.5×
RPRX Royalty Pharma PLC compare 14.0×
MRNA Moderna, Inc. compare 36.9×
RVMD Revolution Medicines, Inc. compare 1,287×
ROIV Roivant Sciences Ltd. compare 2,742×
Biotechnology industry median 9.2×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on REGN